ChengDa Pharmaceuticals Co. Ltd. (301201) - Total Assets
Based on the latest financial reports, ChengDa Pharmaceuticals Co. Ltd. (301201) holds total assets worth CN¥2.41 Billion CNY (≈ $352.46 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore debt repayment capacity of ChengDa Pharmaceuticals Co. Ltd. to assess how comfortably operating cash covers total debt obligations.
ChengDa Pharmaceuticals Co. Ltd. - Total Assets Trend (2019–2024)
This chart illustrates how ChengDa Pharmaceuticals Co. Ltd.'s total assets have evolved over time, based on quarterly financial data. See ChengDa Pharmaceuticals Co. Ltd. (301201) shareholders funds for net asset value and shareholders' equity analysis.
ChengDa Pharmaceuticals Co. Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
ChengDa Pharmaceuticals Co. Ltd.'s total assets of CN¥2.41 Billion consist of 58.1% current assets and 41.9% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 7.3% |
| Accounts Receivable | CN¥94.68 Million | 3.9% |
| Inventory | CN¥135.27 Million | 5.6% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥36.51 Million | 1.5% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how ChengDa Pharmaceuticals Co. Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 301201 market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ChengDa Pharmaceuticals Co. Ltd.'s current assets represent 58.1% of total assets in 2024, an increase from 41.6% in 2019.
- Cash Position: Cash and equivalents constituted 7.3% of total assets in 2024, down from 12.0% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 3.0% in 2019.
- Asset Diversification: The largest asset category is inventory at 5.6% of total assets.
ChengDa Pharmaceuticals Co. Ltd. Competitors by Total Assets
Key competitors of ChengDa Pharmaceuticals Co. Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Alkem Laboratories Limited
NSE:ALKEM
|
India | Rs202.87 Billion |
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥31.82 Billion |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
China | CN¥9.64 Billion |
|
Jilin Aodong Pharmaceutical Group Co Ltd
SHE:000623
|
China | CN¥35.27 Billion |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436
|
China | CN¥1.41 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Zhejiang Medicine Co Ltd
SHG:600216
|
China | CN¥14.18 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
ChengDa Pharmaceuticals Co. Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.95 | 9.93 | 22.78 |
| Quick Ratio | 7.99 | 9.16 | 21.19 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.26 Billion | CN¥1.37 Billion | CN¥1.69 Billion |
ChengDa Pharmaceuticals Co. Ltd. - Advanced Valuation Insights
This section examines the relationship between ChengDa Pharmaceuticals Co. Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.01 |
| Latest Market Cap to Assets Ratio | 0.28 |
| Asset Growth Rate (YoY) | -0.8% |
| Total Assets | CN¥2.44 Billion |
| Market Capitalization | $673.53 Million USD |
Valuation Analysis
Below Book Valuation: The market values ChengDa Pharmaceuticals Co. Ltd.'s assets below their book value (0.28x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: ChengDa Pharmaceuticals Co. Ltd.'s assets decreased by 0.8% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for ChengDa Pharmaceuticals Co. Ltd. (2019–2024)
The table below shows the annual total assets of ChengDa Pharmaceuticals Co. Ltd. from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.44 Billion ≈ $356.53 Million |
-0.77% |
| 2023-12-31 | CN¥2.46 Billion ≈ $359.29 Million |
+5.75% |
| 2022-12-31 | CN¥2.32 Billion ≈ $339.77 Million |
+239.84% |
| 2021-12-31 | CN¥683.23 Million ≈ $99.98 Million |
+27.90% |
| 2020-12-31 | CN¥534.21 Million ≈ $78.17 Million |
-2.26% |
| 2019-12-31 | CN¥546.56 Million ≈ $79.98 Million |
-- |
About ChengDa Pharmaceuticals Co. Ltd.
ChengDa Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates, chemical ingredients, and food and feed additives in China and internationally. It offers process research and development, process optimization, quality and stability research, customized production and other services for pharmaceutical intermediates and APIs; and food… Read more